Biomm S.A Total Assets
Biomm S.A total assets. Based on the latest financial reports, Biomm S.A (BIOM3) holds total assets worth R$485.03 Million BRL (≈ $95.17 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Biomm S.A (BIOM3) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Biomm S.A (2004–2024)
Total assets of Biomm S.A from 2004 to 2024. This chart illustrates how Biomm S.A's total assets have evolved over time, based on quarterly financial data. See today's stock price for Biomm S.A for real-time trading data and today's change.
Biomm S.A - Asset Composition Analysis
Biomm S.A Total Assets Breakdown (December 2024)
Biomm S.A total assets breakdown as of December 2024. Biomm S.A's total assets of R$485.03 Million consist of 52.0% current assets and 48.0% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$72.46 Million | 16.7% |
| Accounts Receivable | R$22.95 Million | 4.9% |
| Inventory | R$54.99 Million | 11.8% |
| Property, Plant & Equipment | R$167.65 Million | 36.0% |
| Intangible Assets | R$45.72 Million | 9.8% |
| Goodwill | R$0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Biomm S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Biomm S.A working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomm S.A's current assets represent 52.0% of total assets in 2024, an increase from 4.2% in 2004.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2024, up from 0.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 2.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 36.0% of total assets.
Biomm S.A Competitors by Total Assets
Key competitors of Biomm S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Biomm S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.45 | 3.36 | 3.03 |
| Quick Ratio | 1.29 | 2.62 | 2.75 |
| Cash Ratio | 0.11 | 0.68 | 0.00 |
| Working Capital | R$153.16 Million | R$188.65 Million | R$134.62 Million |
Biomm S.A - Advanced Valuation Insights
This section examines the relationship between Biomm S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.59 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 35.1% |
| Total Assets | R$465.66 Million |
| Market Capitalization | $159.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biomm S.A's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biomm S.A's assets grew by 35.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biomm S.A (2004–2024)
The table below shows the annual total assets of Biomm S.A from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | R$465.66 Million ≈ $91.37 Million |
+35.09% |
| 2023-12-31 | R$344.70 Million ≈ $67.64 Million |
-14.91% |
| 2022-12-31 | R$405.09 Million ≈ $79.49 Million |
+9.53% |
| 2021-12-31 | R$369.83 Million ≈ $72.57 Million |
-14.98% |
| 2020-12-31 | R$434.97 Million ≈ $85.35 Million |
+11.88% |
| 2019-12-31 | R$388.77 Million ≈ $76.28 Million |
+27.18% |
| 2018-12-31 | R$305.68 Million ≈ $59.98 Million |
+16.50% |
| 2017-12-31 | R$262.39 Million ≈ $51.49 Million |
+10.53% |
| 2016-12-31 | R$237.38 Million ≈ $46.58 Million |
+3.36% |
| 2015-12-31 | R$229.67 Million ≈ $45.07 Million |
+27.91% |
| 2014-12-31 | R$179.56 Million ≈ $35.23 Million |
+30.05% |
| 2013-12-31 | R$138.08 Million ≈ $27.09 Million |
+1870.01% |
| 2012-12-31 | R$7.01 Million ≈ $1.38 Million |
-37.98% |
| 2011-12-31 | R$11.30 Million ≈ $2.22 Million |
+130.32% |
| 2010-12-31 | R$4.91 Million ≈ $962.84K |
-53.95% |
| 2009-12-31 | R$10.66 Million ≈ $2.09 Million |
-12.44% |
| 2008-12-31 | R$12.17 Million ≈ $2.39 Million |
+25.37% |
| 2007-12-31 | R$9.71 Million ≈ $1.90 Million |
-13.00% |
| 2006-12-31 | R$11.16 Million ≈ $2.19 Million |
-29.00% |
| 2005-12-31 | R$15.71 Million ≈ $3.08 Million |
+26.77% |
| 2004-12-31 | R$12.40 Million ≈ $2.43 Million |
-- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more